Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment

References

• Haroche J, Arnaud L, Amoura Z. Erdheim-chester disease. Curr Opin Rheumatol. 2012;24:53–9. doi:10.1097/BOR.0b013e32834d861d. PMID:22089098.
   PubMed Web of Science ®Google Scholar
• Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-chester disease: a comprehensive review of the literature. Orphanet J Rare Dis. 2013;8:137. doi:10.1186/1750-1172-8-137. PMID:24011030.
   PubMed Web of Science ®Google Scholar
• Cives M, Simone V, Rizzo FM, Dicuonzo F, Cristallo Lacalamita M, Ingravallo G, Silvestris F, Dammacco F. Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol. 2015;95:1–11. doi:10.1016/j.critrevonc.2015.02.004. PMID:25744785.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn J-E, Wechsler B, Pérez-Pastor G, Blomberg B, Fuzibet J-G, Dubourguet F, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117:2778–82. doi:10.1182/blood-2010-06-294108. PMID:21239701.
   PubMed Web of Science ®Google Scholar
• Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, Le Toquin S, Bensadoun H, Larousserie F, Silvera S, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116:4070–6. doi:10.1182/blood-2010-04-279240. PMID:20724540.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124:483–92. doi:10.1182/blood-2014-03-561381. PMID:24850756.
   PubMed Web of Science ®Google Scholar
• Darstein F, Kirschey S, Heckl S, Rahman F, Schwarting A, Schuchmann M, Galle PR, Zimmermann T. Successful treatment of erdheim-chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. Intern Med J. 2014;44:90–2. doi:10.1111/imj.12329. PMID:24450524.
   PubMed Web of Science ®Google Scholar
• Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine. 2014;81:175–7. doi:10.1016/j.jbspin.2013.06.013. PMID:23953221.
   PubMed Web of Science ®Google Scholar
• Cohen-Aubart F, Maksud P, Saadoun D, Drier A, Charlotte F, Cluzel P, Amoura Z, Haroche J. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood. 2016;127:1509–12. doi:10.1182/blood-2015-09-672667. PMID:26847247.
   PubMed Web of Science ®Google Scholar
• Podestà MA, Graziani G, Reggiani F, Buemi M, Badalamenti S, Ponticelli C. Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra. Kidney Res Clin Pract. 2014;33:165–7. doi:10.1016/j.krcp.2014.07.007. PMID:26877969.
   PubMedGoogle Scholar
• Goyal G, Shah MV, Call TG, Litzow MR, Wolanskyj-Spinner AP, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Hook CC, et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol. 2017; doi:10.1111/bjh.14997.
   Google Scholar
• Berti A, Cavalli G, Guglielmi B, Biavasco R, Campochiaro C, Tomelleri A, Nicoletti R, Panzacchi A, Ferrarini M, Dagna L. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017;6:e1318237. doi:10.1080/2162402X.2017.1318237. PMID:28680751.
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile J-F, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory erdheim-chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495–500. doi:10.1182/blood-2012-07-446286. PMID:23258922.
   PubMed Web of Science ®Google Scholar
• Cohen Aubart F, Emile J-F, Maksud P, Galanaud D, Cluzel P, Benameur N, Aumaitre O, Amoura Z, Haroche J. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease. Br J Haematol. 2018;180:150–3. doi:10.1111/bjh.14284. PMID:27711968.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Subbiah V, Lockhart AC, Blay J-Y, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, et al. Vemurafenib for BRAF V600-mutant erdheim-chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-basket study. JAMA Oncol. 2018;4:384–8.
   PubMed Web of Science ®Google Scholar
• Estrada-Veras JI, O'Brien KJ, Boyd LC, Dave RH, Durham B, Xi L, Malayeri AA, Chen MY, Gardner PJ, Alvarado-Enriquez JR, et al. The clinical spectrum of erdheim-chester disease: an observational cohort study. Blood Adv. 2017;1:357–66. doi:10.1182/bloodadvances.2016001784. PMID:28553668.
   PubMed Web of Science ®Google Scholar
• Gianfreda D, Musetti C, Nicastro M, Maritati F, Cobelli R, Corradi D, Vaglio A. Erdheim-chester disease as a mimic of igg4-related disease: a case report and a review of a single-center cohort. Medicine (Baltimore). 2016;95:e3625. doi:10.1097/MD.0000000000003625. PMID:27227923.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee M-K, Attar N, Sazegar H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–7. doi:10.1038/nature09626. PMID:21107323.
   PubMed Web of Science ®Google Scholar
• Emile J-F, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, et al. Recurrent RAS and PIK3CA mutations in erdheim-chester disease. Blood. 2014;124:3016–9. doi:10.1182/blood-2014-04-570937. PMID:25150293.
   PubMed Web of Science ®Google Scholar
• Killu AM, Liang JJ, Jaffe AS. Erdheim-chester disease with cardiac involvement successfully treated with anakinra. Int J Cardiol. 2013;167:e115–117. doi:10.1016/j.ijcard.2013.04.057. PMID:23659884.
   PubMed Web of Science ®Google Scholar
• Franconieri F, Martin-Silva N, de Boysson H, Galateau-Salle F, Emile J-F, Bienvenu B, Aouba A. Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in erdheim-chester disease: Towards the paradigm of combined targeting and immune therapies. Acta Oncol. 2016;55:930–2. doi:10.3109/0284186X.2015.1120885. PMID:27031008.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Brody L, Arcila M, Bowers C, Fluchel M. Anakinra as efficacious therapy for 2 cases of intracranial erdheim-chester disease. Blood. 2016;128:1896–8. doi:10.1182/blood-2016-06-725143. PMID:27535996.
   PubMed Web of Science ®Google Scholar
• Tran TA, Pariente D, Lecron JC, Delwail A, Taoufik Y, Meinzer U. Treatment of pediatric erdheim-chester disease with interleukin-1-targeting drugs. Arthritis Rheum. 2011;63:4031–2. doi:10.1002/art.30638. PMID:21898344.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, Vitale A, Bacherini D, Vannozzi L, Emmi L, D'Elios MM, Cantarini L, Prisco D. Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection. Int J Dermatol. 2017;56:218–20. doi:10.1111/ijd.13337. PMID:27336860.
   PubMed Web of Science ®Google Scholar
• Chang Z, Spong CY, Jesus AA, Davis MA, Plass N, Stone DL, Chapelle D, Hoffmann P, Kastner DL, Barron K, et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis & Rheumatology (Hoboken, NJ). 2014;66:3227–32. doi:10.1002/art.38811.
   PubMed Web of Science ®Google Scholar
• Kullenberg T, Löfqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford). 2016;55:1499–506. doi:10.1093/rheumatology/kew208. PMID:27143789.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Vitale A, Iannone F, Cantarini L. Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. Clin Exp Rheumatol. 2016;34:353. PMID:26940429.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Baldissera E, Dagna L. Efficacy and safety of biological agents in adult-onset Still's disease. Scand J Rheumatol. 2015;44:309–14. doi:10.3109/03009742.2014.992949. PMID:25656459.
   PubMed Web of Science ®Google Scholar
• Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-Cin E, Campochiaro C, Guglielmi B, Berti A, Lampasona V, von Deimling A, et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis. 2015;74:1596–602. doi:10.1136/annrheumdis-2013-204924. PMID:24671772.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Biavasco R, Borgiani B, Dagna L. Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease. Front Immunol. 2014;5:281. doi:10.3389/fimmu.2014.00281. PMID:24982657.
   PubMed Web of Science ®Google Scholar
• Aouba A. KRASG12D, pulmonary LCH, and atorvastatin. Blood. 2017;130:391–2. doi:10.1182/blood-2017-06-788455. PMID:28751357.
   PubMed Web of Science ®Google Scholar
• Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012;18:5329–40. doi:10.1158/1078-0432.CCR-12-1632. PMID:22850568.
   PubMed Web of Science ®Google Scholar
• Murakami I, Matsushita M, Iwasaki T, Kuwamoto S, Kato M, Nagata K, Horie Y, Hayashi K, Imamura T, Morimoto A, et al. Interleukin-1 loop model for pathogenesis of langerhans cell histiocytosis. Cell Commun Signal. 2015;13:13. doi:10.1186/s12964-015-0092-z. PMID:25889448.
   PubMed Web of Science ®Google Scholar
• Cavalli G, De Luca G, Dagna L. Advances in potential targeted therapies for erdheim-chester disease. Expert Opin Orphan Drugs. 2017;5:253–60. doi:10.1080/21678707.2017.1285226.
   Web of Science ®Google Scholar
• Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE. 2011;6:e22769. doi:10.1371/journal.pone.0022769. PMID:21829508.
   PubMed Web of Science ®Google Scholar